Delamanid: A Review of Its Use in Patients with Multidrug-Resistant Tuberculosis
Delamanid: A Review of Its Use in Patients with Multidrug-Resistant Tuberculosis
复制标题
DOI：
10.1007/s40265-014-0331-4
复制
发表时间：
2015-01-01
期刊：
影响因子：
11.5
通讯作者：
Scott, Lesley J.
中科院分区：
文献类型：
--
作者：
Blair, Hannah A.;Scott, Lesley J.
Delamanid（Deltyba（R））是一种硝基咪唑并恶唑衍生物，具有较强的体内外抗结核活性。它已在包括日本和欧盟在内的多个国家获得批准，可作为耐多药结核病（MDR-TB）成人患者适当联合治疗方案的一部分，因为耐药性或耐受性无法组成有效的治疗方案。在MDR-TB成人患者中进行的一项稳健的II期试验中，口服delamanid 100 mg，每日两次，持续2个月，加上优化的背景方案，与安慰剂相比，显著提高了痰培养转化率。在一项为期6个月的扩展研究中，长期（
Delamanid (Deltyba (R)), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and those of the EU, for use as part of an appropriate combination regimen in adults with multidrug-resistant tuberculosis (MDR-TB) when an effective treatment regimen cannot otherwise be composed due to resistance or tolerability. In a robust phase II trial in adult patients with MDR-TB, oral delamanid 100 mg twice daily for 2 months plus an optimized background regimen improved sputum culture conversion rates to a significantly greater extent than placebo. In a 6-month extension study, long-term (